About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Don't Wait - Patent Today! | Main | A Rough Business »

December 11, 2002

A Quick One While He's Away

Email This Entry

Posted by Derek

This is one of those nights I warned about, when there's not much time for blogifying. My book chapter is headed out via overnight delivery tomorrow, full of corrections. That's not as bad as it sounds - they're things like a missed patronymic initial on a Soviet-era reference's co-author's name. A few are larger than that, but not too much larger. Considering some of the galley-proof horror stories I've heard, I consider myself quite fortunate.

And this is another one of those times I'd like to be able to talk about my work without being fired, because there's a lot of interesting stuff happening on that front, too. Oh, well, you'll have to wait to read the J. Med. Chem. paper. Who am I kidding - you'll probably read it in "Acta Retracta", if at all (you can tell if someone's a scientific literature geek by whether or not they laugh at that line, in much the same way that no synthetic organic chemist can avoid cracking a smile at the phrase "plutonium enolate.")

Or you can, if you're a real masochist, read the patent when it comes out. Speaking of which, I just downloaded a key patent the other day, with a lot of bearing on my current work, which turns out to an unrelieved torrent of hundreds of pages of Japanese. I truly hate it when that happens, because a patent that huge is bad enough in English. I can actually plow through katakana, which a lot of chemical names and concepts are rendered in, but there's no remedy for this beast, other than really being able to read Japanese. Fortunately, a couple of my co-workers do, being Japanese themselves. Unfortunately, they tend to shut their doors when they hear me coming.<

Comments (0) + TrackBacks (0) | Category: Life in the Drug Labs



Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry